Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Cholinergic anthelmintics: Tachyphylaxis mechanisms and control in a parasitic nematode model,Brugia malayi

Award Number: R21AI173819
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/15/2023
PERIOD OF PERFORMANCE END DATE: 11/30/2025

Group Awards By:

View Award Description

Cholinergic anthelmintics: Tachyphylaxis mechanisms and control in a parasitic nematode model,Brugia malayi - Project Summary Soil-transmitted helminth infections are a global concern for public health and affect over 1 billion people worldwide. Infections caused by Ascaris lumbricoides, Trichuris trichiura (whipworms), and Ancylostoma duodenale (hookworms) affect people in warm and moist climates often lacking in hygiene and sanitation and in temperate zones during warmer months. Infected children develop severe malnutrition and show severe physical and cognitive growth. Control of these parasites depends on the administration of anthelmintic drugs like benzimidazoles like albendazole, macrocyclic lactone, ivermectin, and nicotinic agonists like levamisole and pyrantel. The development of resistance to these anthelmintics poses a great challenge in controlling the transmission of these diseases. Parasitic nematodes are complex organisms that adopt complex mechanisms to resist exposure to anthelmintic drugs. We have identified tachyphylaxis as one mechanism the parasite utilizes to resist and recover motility in the continued exposure to the cholinergic anthelmintic levamisole. The endoplasmic reticulum retention protein, NRA-2, is one of the proteins implicated in modulating tachyphylaxis in the female Brugia malayi parasites. The transcription factor, DAF-12 is upregulated in tachyphylactic worms and could play a key role in mediating tachyphylaxis. Macrocyclic lactone, abamectin, has limited effect on its own on the motility of adult B. malayi but, when applied in combination with levamisole, prevents tachyphylaxis and recovery of motility. Here, we propose, Aim #1: To test the hypothesis that DAF-12 mediates tachyphylaxis in B. malayi. We will knockdown daf-12 in adult B. malayi to determine its role in mediating tachyphylaxis. We will measure transcript levels of nra-2 in daf-12 knockdown worms to determine the role of DAF-12 in regulating the expression of nra-2. We will also target DAF-12 using agonists to prevent tachyphylaxis. Aim #2: To test the hypothesis that muscle calcium concentrations & calcium release mechanisms produced by levamisole are changed in the presence of macrocyclic lactones. We will investigate the effects of macrocyclic lactones, abamectin, ivermectin, and moxidectin in prolonging the paralysis induced by levamisole. We will evaluate the change in calcium release mechanisms due to macrocyclic lactones by performing RNAi of the ryanodine and the IP3 receptors, unc-68 and itr-1 in B. malayi, and performing in vivo calcium imaging using C. elegans. At the end of these experiments, we will have characterized DAF-12 as a novel anthelmintic target that could help prevent cholinergic tachyphylaxis. We would have an insight into the effect of macrocyclic lactones on levamisole calcium release mechanisms in nematode muscle. These studies will provide an improved mechanistic insight into cholinergic tachyphylaxis and a rational avenue to prevent worm recovery and resistance.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$7 )
2026	2024	CREIGHTON UNIVERSITY	2500 CALIFORNIA PLAZA	OMAHA	NE	68178	DOUGLAS	USA	Allergy and Infectious Diseases Research	000	3	3/31/2026	NON-COMPETING CONTINUATION	-$7
														Subtotal = -$7

Issue Date FY: 2024 ( Subtotal = $216,154 )
2024	2024	CREIGHTON UNIVERSITY	2500 CALIFORNIA PLAZA	OMAHA	NE	68178	DOUGLAS	USA	Allergy and Infectious Diseases Research	002	3	5/21/2024	NON-COMPETING CONTINUATION	$223,622
2024	2023	CREIGHTON UNIVERSITY	2500 CALIFORNIA PLAZA	OMAHA	NE	68178	DOUGLAS	USA	Allergy and Infectious Diseases Research	001	2	3/7/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$186,846
2024	2023	IOWA STATE UNIVERSITY OF SCIENCE AND TECHNOLOGY	1350 BEARDSHEAR HALL	AMES	IA	50011	STORY	USA	Allergy and Infectious Diseases Research	000	1	3/7/2024	NEW	-$194,314
2024	2023	IOWA STATE UNIVERSITY OF SCIENCE AND TECHNOLOGY	1350 BEARDSHEAR HALL	AMES	IA	50011	STORY	USA	Allergy and Infectious Diseases Research	004	1	8/13/2024	NEW	-$5,622
2024	2023	CREIGHTON UNIVERSITY	2500 CALIFORNIA PLAZA	OMAHA	NE	68178	DOUGLAS	USA	Allergy and Infectious Diseases Research	005	2	8/13/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$5,622
2024	2023	IOWA STATE UNIVERSITY OF SCIENCE AND TECHNOLOGY	1350 BEARDSHEAR HALL	AMES	IA	50011	STORY	USA	Allergy and Infectious Diseases Research	003	1	7/17/2024	NEW	$0
														Subtotal = $216,154

Issue Date FY: 2023 ( Subtotal = $219,388 )
2023	2023	IOWA STATE UNIVERSITY OF SCIENCE AND TECHNOLOGY	515 MORRILL RD, 1350 BEARDSHEAR HALL	AMES	IA	50011	STORY	USA	Allergy and Infectious Diseases Research	000	1	6/15/2023	NEW	$219,388
														Subtotal = $219,388

Grand Total All Awards = $435,535

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Cholinergic anthelmintics: Tachyphylaxis mechanisms and control in a parasitic nematode model,Brugia malayi

Award Number: R21AI173819

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/15/2023

PERIOD OF PERFORMANCE END DATE: 11/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer